MicroTech Medical (Hangzhou) Co

MicroTech Medical (Hangzhou) Co Current Assets

The Current Assets of MicroTech Medical (Hangzhou) Co (2235.HK) as of Oct 29, 2026 is 1.93 B CNY. In the previous year, Current Assets was 2.22 B CNY — a change of -12.79% (lower).

Current Assets

1.93 BCNY

YoY

-12.79%

Last updated:

Current Assets of MicroTech Medical (Hangzhou) Co is 2025 1.93 B CNY. Current Assets of MicroTech Medical (Hangzhou) Co was 2024 2.22 B CNY. It decreases by -12.79% lower compared to the previous year.

The MicroTech Medical (Hangzhou) Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
238.31 M CNY
Jan 1, 2020
801.04 M CNY
Jan 1, 2021
2.60 B CNY
Jan 1, 2022
2.53 B CNY
Jan 1, 2023
2.35 B CNY
Jan 1, 2024
2.22 B CNY
Jan 1, 2025
1.93 B CNY
The MicroTech Medical (Hangzhou) Co Current Assets history
YEARCurrent AssetsYoY
1.93 BCNY-12.79%
2.22 BCNY-5.69%
2.35 BCNY-7.19%
2.53 BCNY-2.68%
2.60 BCNY+224.63%
801.04 MCNY+236.13%
238.31 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroTech Medical (Hangzhou) Co Stock analysis

What does MicroTech Medical (Hangzhou) Co do? MicroTech Medical (Hangzhou) Co., Ltd. generates revenue through the sale of diabetes management medical devices and consumables, including the Equil applicator insulin pump system, blood glucose monitoring systems, and the AiDEX G7 continuous blood glucose monitoring system. These products are commercialized for overseas markets such as the United States and the European Union, targeting healthcare providers and patients seeking advanced diabetes care solutions. The company's R&D efforts focus on developing products like the artificial pancreas, which remains in the research phase but is expected to contribute to future revenue streams. The firm's primary customers are healthcare institutions and end-users in international markets, with a strong emphasis on the United States and European Union regions. By leveraging its established product portfolio, MicroTech Medical capitalizes on the growing demand for innovative diabetes management solutions, ensuring consistent revenue from both existing and emerging product lines. The company's IPO in 2021 provided additional capital to support further development and market expansion. MicroTech Medical (Hangzhou) Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroTech Medical (Hangzhou) Co stock

Current Assets of MicroTech Medical (Hangzhou) Co is 1.93 B CNY in 2025.

Current Assets of MicroTech Medical (Hangzhou) Co changed from 2.22 B CNY to 1.93 B CNY, representing a -12.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets MicroTech Medical (Hangzhou) Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's MicroTech Medical (Hangzhou) Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MicroTech Medical (Hangzhou) Co

All Key Metrics — MicroTech Medical (Hangzhou) Co